Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by InnoCare Pharma

< Previous 1 2 Next >
InnoCare to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From InnoCare Pharma
Via Business Wire
InnoCare Appoints Xin Fu as Chief Financial Officer
From InnoCare Pharma
Via Business Wire
InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-332 Meet Primary Endpoint in Patients with Atomic Dermatitis
From InnoCare Pharma
Via Business Wire
Latest Data of InnoCare’s Oncology Pipelines Presented at the 65th Annual Meeting of ASH
From InnoCare Pharma
Via Business Wire
10 Studies on InnoCare’s Oncology Pipelines Selected at the Upcoming 65th Annual Meeting of ASH
From InnoCare Pharma
Via Business Wire
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of Orelabrutinib for the Treatment of ITP in China
From InnoCare Pharma
Via Business Wire
InnoCare Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189 in Combination with EGFR Inhibitor Furmonertinib
From InnoCare Pharma
Via Business Wire
InnoCare Releases 2023 Interim Results and Business Highlights
From InnoCare Pharma
Via Business Wire
InnoCare Announces Approval of Clinical Trial of pan-TRK Inhibitor Zurletrectinib for the Treatment of Pediatric Patients in China
From InnoCare Pharma
Via Business Wire
InnoCare Announces First Psoriasis Patient Dosed in Clinical Trial of TYK2 Allosteric Inhibitor ICP-488 in China
From InnoCare Pharma
Via Business Wire
Latest Data of InnoCare’s Orelabrutinib Presented at the 17th International Conference on Malignant Lymphoma (ICML)
From InnoCare Pharma
Via Business Wire
InnoCare Announces Orelabrutinib Becomes the First and the Only BTK Inhibitor Approved in China for the Treatment of R/R MZL
From InnoCare Pharma
Via Business Wire
InnoCare Announces First Subject Dosed in Clinical Trial of Novel Targeted Protein Degrader ICP-490 in China
From InnoCare Pharma
Via Business Wire
InnoCare Releases 2022 Annual Results and Business Highlights
From InnoCare Pharma
Via Business Wire
InnoCare Announces First Subject Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in China
From InnoCare Pharma
Via Business Wire
InnoCare and Keymed Jointly Announce First Subject Dosed in Clinical Trial of CCR8 Monoclonal Antibody ICP-B05
From InnoCare Pharma
Via Business Wire
Phase II Study of Orelabrutinib in Patients with R/R CLL/SLL Published by American Journal of Hematology
From InnoCare Pharma
Via Business Wire
Latest Clinical Data of InnoCare’s Gunagratinib Presented at 2023 ASCO GI
From InnoCare Pharma
Via Business Wire
InnoCare Announces Approval of Tafasitamab in Combination With Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong
From InnoCare Pharma
Via Business Wire
InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Orelabrutinib in Combination with Tafasitamab + Lenalidomide in China
From InnoCare Pharma
Via Business Wire
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore
From InnoCare Pharma
Via Business Wire
InnoCare Releases 2022 Third Quarter Results: Star Board Listing for Long-term Growth and Rapid Increase of Orelabrutinib Sales
From InnoCare Pharma
Via Business Wire
10 Studies on Orelabrutinib Selected at the Upcoming 64th Annual Meeting of ASH
From InnoCare Pharma
Via Business Wire
InnoCare Announces First Adolescent Patient Dosed in Clinical Trial of pan-TRK Inhibitor ICP-723 in China
From InnoCare Pharma
Via Business Wire
InnoCare Completes Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
From InnoCare Pharma
Via Business Wire
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in China
From InnoCare Pharma
Via Business Wire
InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
From InnoCare Pharma
Via Business Wire
InnoCare Announces Priority Review of Orelabrutinib for the Treatment of R/R MZL by NMPA
From InnoCare Pharma
Via Business Wire
InnoCare Announces the Acceptance of the Biologics License Application for Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong
From InnoCare Pharma
Via Business Wire
InnoCare and Keymed Jointly Announce Approval of Clinical Trial of CCR8 Monoclonal Antibody CM369
From InnoCare Pharma
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.